The sleep medicine community has increasingly recognized the necessity that clinical care be based on high-quality levels of evidence. Although research supports a favorable influence of positive airway pressure (PAP) therapy on risk for significant adverse outcomes in patients with severe obstructive sleep apnea-hypopnea (OSAH), welldesigned trials are still required to elucidate the effect of PAP on health, quality of life, and economic risks in patients with milder OSAH. Similarly, although there is strong evidence supporting various PAP titration strategies and PAP modalities in patients with severe OSAH without significant medical and psychiatric comorbidities, there is insufficient high-level evidence assessing and comparing the clinical efficacy and health care cost implications of various titration paradigms and various PAP modalities in individuals with milder OSAH and those with comorbid conditions. For ethical and other reasons, it may not be possible to apply a randomized controlled design to address all questions. However, whichever design is employed, it must be rigorously developed with attention to all potential confounders with adequate power to provide compelling, high-quality evidence.Keywords: obstructive sleep apnea; positive airway pressure; therapy of sleep apnea Wright and colleagues generated considerable self-examination within the field of sleep medicine with the publication of their literature review of the health consequences of obstructive sleep apnea-hypopnea (OSAH) and the effectiveness of continuous positive airway pressure (CPAP) therapy for this disorder (1). The authors concluded that perhaps with the exception of reducing sleepiness and motor vehicle crashes, evidence of benefit from treatment with CPAP was, at best, weak. Wright and coworkers supported their contention by citing numerous flaws in the studies that were published to that time. Inadequacies were identified in research design and analyses, including lack of randomized controlled trials, as well as failure to account for carryover effects and potential confounders.It is evident that well-designed and conducted randomized controlled trials (RCTs) yield high-quality evidence, but they carry costs as well as benefits. Several authors (2-4) have asserted that the hierarchy of research design quality, as reflected by the evidence-grading pyramid, is flawed and artificial, with the results of many well-done non-RCTs withstanding the test of time. It has been further argued that RCT design may rigidly restrict the intervention to a single paradigm, whereas in clinical practice, physicians adjust therapies according to the specific clinical features of individual patients (2, 4). Thus, the generalizability of the results of randomized controlled clinical trials to clinical care may be imperfect. Moreover, these authors contended that similar evidence from more than one, well-done observational study usually corroborates the results of an RCT examining the same issue. RCTs are also usually costly (5) and, if comparably re...